Anti-CGRP therapies for migraine Learning Zone

Migraine, which affects over one billion people worldwide,¹ manifests as repeating episodes of headache of moderate-to-severe pain intensity, persisting approximately 4–72 hours².

Mounting evidence suggests that migraine pathogenesis recruits the trigeminal nerve and its projections to the intracranial vasculature³. Discovery of signalling molecules involved in migraine pathogenesis led to the development of mechanism-based therapies³, such as anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies and small-molecule antagonists.

This Learning Zone focuses on the unmet needs and disease burden associated with migraine, the role of CGRP in migraine pathophysiology, and anti-CGRP therapies for acute and prophylactic treatment of migraine.

Meet the patient consultants

Play this short video introduction to Helen and Caitlin, two women living in the UK with migraine. Throughout this Learning Zone, Helen and Caitlin share their lived experience of migraine, and their insights on migraine management and the effectiveness of available treatments.

References

1. Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, Al-Raddadi RM, et al. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954–976.
2. Headache Classification Committee of the International Headache Society (IHS) the International Classification of Headache Disorders, 3rd edition. Cephalal. 2018;38:1–211.
3. Ashina M, Hansen JM, Do TP, Melo-Carrillo A, Burstein R, Moskowitz MA. Migraine and the trigeminovascular system—40 years and counting. Lancet Neurol. 2019;18(8):795–804.